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Abstract
Randomized experiments play a major role in data-driven decision making across
many different fields and disciplines. In medicine, for example, randomized controlled
trials (RCTs) are the backbone of clinical trial methodology for testing the efficacy
of new drugs and therapies versus existing treatments or placebo. In business and
marketing, randomized experiments are typically referred to as A/B tests when there
are only two arms, or variants, in the experiment, and as multivariate A/B tests when
there are more than two arms. Typical applications of A/B tests include comparing
the effectiveness of different ad campaigns, evaluating how people respond to different
website layouts, or comparing different customer subpopulations to each other.
This paper focuses on multivariate A/B testing from a digital marketing perspec-
tive, and presents a method for the sequential monitoring of such experiments while
accounting for the issue of multiple comparisons. In adapting and combining the meth-
ods of two previous works, the method presented herein is straightforward to implement
using standard statistical software and performs quite well in various simulation studies,
exhibiting better power and smaller average sample sizes than comparable methods.
Introduction
In traditional A/B testing, a researcher conducts a randomized experiment with two arms,
or variants, A and B, which can be thought of as the control and treatment group, re-
spectively. The objective of the experiment is to determine if the people randomized to
group B performed better towards some outcome or goal than did the people randomized
to the control group, A. One simple example of this would be a clinical trial for patients
with high blood pressure testing the efficacy of some new high blood pressure medication
versus placebo. Researchers would be interested in knowing whether the group receiving
the new medication, group B, saw its members experience a greater reduction in blood
pressure levels than did the placebo group, group A. In perhaps a more familiar marketing
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setting, a typical example might be assigning one group of people, group B, to be shown a
certain advertisement while the control group, group A, is not shown that ad. The marketer
might then be interested in, say, knowing if group B exhibited an increase in some type of
purchasing behavior compared to the control group, group A.
A multivariate A/B test extends the standard A/B test to include more than one treatment
group, but still has only one control group. Let the control group continue to be denoted
as group A, then the different arms, or variants, in a multivariate A/B test can be thought
of as: A, Bi, i = 1, 2, ...,m, where m is some arbitrary number of variants (excluding the
control group) to be included in the experiment. As before, an example of a multivariate
A/B test might be the same clinical trial for high blood pressure medication, but with three
new candidate treatments each being compared against baseline, instead of just one.∗ Sim-
ilarly, in the context of marketing, a multivariate A/B test would look very much like the
previous marketing example, but with, say, four or five different creative types each being
compared against the control group, A.
When there are multiple arms in an experiment there are a number of questions a researcher
might hope to answer. Some of those questions could include the following:
• What is the best performing variant?
• What are the top three performing variants?
• From a statistical testing standpoint, is each variant significantly better than baseline?
• How do the variants compare to each other?
• For each variant, what is the probability that it is the best performing variant?
The above questions come in addition to the usual questions that arise when undertaking
a classical two-arm A/B test, such as:
• How many people do I need in each group to detect a statistically significant difference?
• When I’m calculating my sample size, how do I know how big of a difference I want
to detect?
• Can I stop as soon as there’s a significant difference between groups?
• How soon can I look at the data from this experiment?
∗Throughout this paper, baseline and control will be used interchangeably and are taken to mean the
same thing. The baseline success rate, for example, is equal to the success rate in the control group.
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In the rest of this paper, I outline my proposed methodology for multivariate A/B testing
and how it addresses each of the questions outlined above. I begin with a brief overview
of statistical hypothesis testing and the different study designs that can be implemented
in hypothesis testing under a simple two-arm A/B test. I then present the proposed mul-
tivariate A/B testing methodology followed by results for that methodology applied to
simulated multivariate A/B experiments, and close with a discussion of possible extensions
and additions to this methodology.
Methodology
Overview
At its core, a standard two-arm A/B test is a simple statistical hypothesis test. Denote the
null hypothesis by H0 and the alternative hypothesis by H1. The hypotheses being tested
then are typically either:
1. H0 : Groups A and B perform identically towards the same goal of interest
vs.
H1 : Groups A and B do not perform identically towards the same goal of interest,
or
2. H0 : Group A performs no worse than group B towards the same goal of interest
vs.
H1 : Group B performs better than group A towards the same goal of interest.
For clarity, assume a digital marketer is interested in converting customers to the latest
upgrade of his company’s product. To do this, he wants to launch a new campaign aimed
at generating conversions. But before launching this campaign to all customers he wants to
be sure it will work, so he first decides to conduct an A/B test wherein some customers are
randomly assigned to see the new ad (group B) and some are not (group A). Let µA denote
the conversion rate in the control group, A, and µB the conversion rate in the exposed
group, B. Then the marketer’s A/B test will look to test either:
1. H0 : µA = µB vs. H1 : µA 6= µB
or
2. H0 : µA ≥ µB vs. H1 : µA < µB
To formally test either of these hypotheses there are a few analytical approaches to consider.
First note that in the marketing example provided, customer conversion rates are being
analyzed. This means that the outcome variable is dichotomous (yes or no, 0 or 1, etc.). For
each individual in the experiment, the outcome variable of interest is the variable capturing
3
whether this person installed the latest upgrade, yes or no. To compare the two groups, the
analysis could take the form of a Z-test for the comparison of two proportions (assuming
the sample size in each group is large enough), Fisher’s exact test for the comparison of
two proportions, a simple Bayesian analysis comparing the posterior distributions of two
Beta distributions, or if there are other variables that should be considered in the model
then perhaps a logistic regression wherein a statistical test is conducted on the coefficient
of interest via, e.g., a Wald test or a likelihood ratio test, etc.
Study Design
In addition to the analytic method, the researcher also needs to decide on a study design.
The study design could take the form of a fixed-sample size design, or a sequential sample
size design (with or without adaptive randomization) [1, Ch. 87]. In a fixed-sample design,
the number of individuals, or customers, to be enrolled in the experiment is fixed a priori
based on a sample size calculation prior to the start of the experiment [1, Ch. 87]. That
calculation will depend on a number of factors, including: an estimate of the treatment
effect (i.e., how much better/worse the exposed group will perform compared to the control
group), an estimate of the baseline success (conversion) rate in the control group, the de-
sired Type I error rate for the test (α), the desired power to detect the estimated treatment
effect (power = 1 - Type II error rate), and the proportion of individuals to be randomized
to each group (e.g. 50% in each group, 60%/40%, etc) [2]. In a fixed-sample size design,
no conclusions regarding the hypotheses being tested can be drawn until the full sample
has been accrued in each group, otherwise the Type I error will be greatly inflated beyond
the pre-specified level [3, 4]. Additionally, the proportion of individuals randomized to each
arm of the experiment will typically remain fixed throughout the experiment. The fixed
design is often referred to as a traditional [4] or conventional [2] study design, and it is how
most experimental trials are carried out [1, Ch. 87].
A sequential sample size design, sometimes also called an adaptive [2] or flexible design
[4], will monitor the data accrued throughout the experiment either continuously, or at
administratively convenient intervals in order to make decisions about the future course of
the study while the study is underway [4]. At each interim point, a decision can be made
regarding whether the experiment should be stopped because the treatment arm has shown
itself to be either a clear winner or loser with respect to the control group. If there are
multiple treatment arms in the study, decisions can also be made regarding the re-allocation
of individuals to different arms of the experiment by altering the assignment probabilities
so that more people are randomized to better performing arms as the study is ongoing,
or by completely dropping arms that are exhibiting a very high probability that they are
ineffective.† Under such a design, the sample size of the study is typically not determined
†Note that throughout the rest of this document, unless otherwise stated, the term adaptive will only be
used with respect to adaptive randomization, i.e. continuously updating the randomization of individuals
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and fixed a priori, though in many cases a maximum sample size will be defined a pri-
ori in order to keep the size of the experiment manageable. Similarly, in some cases the
postulated treatment effect need not be provided as well. However the desired power and
Type I error rate will play a role in study design, and adjustments need to be made to
classical test statistics to avoid inflating the Type I error of the test. For studies in which
the experimenter has pre-determined when and how many interim looks at the data there
will be, a common frequentist approach to controlling the Type I error of a sequentially-
designed study is to specify an alpha spending function [5], examples of which include the
Pocock [6], Peto [7], and O’Brien-Fleming [8] spending functions. Several sequential and
adaptive Bayesian approaches also exist [e.g. 9, 10, 11, 12], though many Bayesian designed
studies will ultimately use thresholds corresponding to frequentist characteristics, making
the results of the experiment difficult to interpret [13].
Among sequential tests that do not require a sample size to be calculated a priori, perhaps
the most well-known is Wald’s sequential probability ratio test (SPRT) [14], which allows
for continuous monitoring of a test between two pre-specified hypotheses, with the experi-
ment terminating when the test statistic crosses one of two thresholds - one corresponding to
accepting the null hypothesis, and the other the alternative. The test, however, only consid-
ers two simple hypotheses, and is therefore challenging to apply in the more commonplace
scenarios of composite hypotheses presented above, for example. Several extensions to the
SPRT have been developed [e.g. 15, 16, 17], and many of these do extend the SPRT to
allow for one-sided hypothesis testing. An alternative, but very similar approach was de-
veloped by Cheng and Shen [18] under a Bayesian decision-theoretic framework, which is
very appealing for the problem presented here, and which I discuss in more detail below.
Sequential Monitoring in A/B Testing
While fixed-sample designs have historically been the most popular approach, sequential de-
signs have been around since the first half of last century - for roughly 70 years dating back to
Wald’s SPRT [14] in 1945, and there are several other examples of this type of methodology
and/or extensions of the original SPRT in the literature [see, e.g., 14, 15, 16, 17, 19, 20, 21, to
name a few]. The appeal of sequential sample size designs is that, on average, they allow re-
searchers to answer questions with smaller sample sizes than do fixed sample size designs [1,
Ch. 87]. The reason, however, that fixed sample designs have been most popular is because
sequential sample size designs are limited to settings where outcomes can be categorized as
successes or failures, and where that categorization can be made shortly after enrollment in
the study. The categorization is important, because continuing the experiment to include
the next person or group of persons is dependent on being able to observe the outcome of
to treatment groups based on how well each group has performed up until that point - better performing
groups would receive more subjects, poorly performing groups fewer. This is known as outcome-adaptive
randomization [1, Ch. 88]. More on this in the Discussion section.
5
all people that have previously participated in the study [1, Ch. 87]. Sequential designs
are only feasible when there is a large group of people who are suitable to be participants
in the study in short order following the observed outcomes of those who have already par-
ticipated in the study. Additionally, each study participant’s outcome must be observable
in a short amount of time following entry to the study, and the treatments (or variants)
administered to the exposed group(s) can’t extend over a long period of time because the
length of the study would be increased dramatically, which would be quite impractical [1,
Ch. 87]. Further, if a researcher was also implementing an adaptive randomization scheme
on top of the sequential design, a study taking place over too long a period of time could
become subject to drift which could cause the adaptive randomization to perform poorly
and bias results [11].
A great deal of literature on study design and hypothesis testing can be found not just in
purely statistical journals, but also biostatistical and medical journals. This is attributable
to the development of clinical trial methodology in the medical field; after all, what is a
clinical trial but a (possibly multivariate) A/B test comparing the performance of one or
more drugs for treating a particular disease to a placebo or other type of control group.
This, then, explains why so many experiments take on a fixed-sample design. It can be
very challenging, both administratively and analytically, to conduct a sequential or adap-
tive clinical trial because of either patient recruitment/enrollment issues, or if the outcome
of interest isn’t immediately available after administering a treatment to a patient, or if
administering the treatment is a process that takes several weeks. That said, there is a
sizable amount of research on sequential and adaptive designs in clinical trials (most of the
works cited to this point, for example), and interest is continually growing as researchers are
constantly looking for better ways to more quickly and ethically identify the most helpful
treatments for numerous life-threatening diseases and conditions. Indeed, a PubMed search
shows a steady increase in the number of publications containing the phrases “sequential
design” and “adaptive design” over the past 25+ years [22].
Therefore, when looking to develop a method for a multivariate A/B testing procedure, it
was natural to look to the medical and clinical trials literature. In particular, I opted to
base the methodology on the work of Cheng and Shen [18] by generalizing their method to
accommodate a multivariate A/B test.
A Bayesian Sequential Design for A/B Testing
The title of this section plays on the title of Cheng’s and Shen’s 2005 paper, Bayesian Adap-
tive Designs for Clinical Trials [18]. Despite their use of the word “adaptive” in the title,
they do not develop nor implement adaptive procedures in the way defined here. Rather,
they develop a Bayesian theoretic approach to a sequential two-arm clinical trial, or A/B
test, in which the total sample size in the experiment is not fixed a priori, nor is a maximum
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sample size imposed. Their method is as follows [18].
Consider a one-sided hypothesis test similar to those defined earlier in which the researcher
wishes to test:
H0 : µA + θ0 ≥ µB vs. H1 : µA < µB.
Define θ = µB−µA, where, as before, µB represents the average response rate in the exposed
group, B; µA represents the average response rate in the control group, A; and θ0 is some
constant ≥ 0. For simplicity let θ0 = 0 throughout, so that the hypothesis test can be
rewritten as:
H0 : θ ≤ 0 vs. H1 : θ > 0.
Let A and R denote the actions of either accepting or rejecting the null hypothesis, respec-
tively. The authors then define the following loss functions:
L(θ,A) =
{
0, if θ ≤ 0;
K1, if θ > 0;
L(θ,R) =
{
K0, if θ ≤ 0;
0, if θ > 0;
where K0 and K1 are the losses for making a Type I and Type II error, respectively.
The goal is to devise a stopping rule to minimize the loss. Define Xj = {X1, . . . , Xj} as
the cumulative data collected up to step j of the experiment (in other words, after j looks
at the data), and define the corresponding information set at that time as the σ-algebra
Fj = σ(Xj). The total cost (or loss) of stopping the experiment after the j-th look at the
data is the cost of enrolling everyone in the study up to and including that point, plus
the loss of either accepting or rejecting the the null hypothesis at that point, whichever is
smaller:
Lstop(Xj) = 2K2
j∑
i=1
Bi + min
[
E{L(θ,A)|Fj}, E{L(θ,R)|Fj}
]
, (1)
whereK2 is the cost of enrolling one person into the study, andBi is the number of additional
people involved in the study between looks i − 1 and i of the experiment. Further, note
that
E{L(θ,A)|Fj} = K1P (θ > 0|Fj) and E{L(θ,R)|Fj} = K0P (θ ≤ 0|Fj).
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The loss of continuing the experiment to allow for a (j + 1)-th look at the data can be
expressed as:
Lcont(Xj) = 2K2
j+1∑
i=1
Bi + E
(
min
[
E{L(θ,A)|Fj+1}, E{L(θ,R)|Fj+1}
]∣∣∣Fj), (2)
where the outside expectation in (2) is taken with respect to the posterior predictive distri-
bution of θ.
The decision to reject or accept the null hypothesis at the j-th look would proceed as follows:
If the expected loss of accepting the null hypothesis at step j is less than or equal to the
expected loss of rejecting the null hypothesis at step j, then accept the null; otherwise,
reject. Notationally, the rejection region, Rj , can be defined as:
Rj =
{
Xj : P (θ > 0|Fj)
P (θ ≤ 0|Fj) ≥
K0
K1
}
, j = 1, 2, . . . (3)
The authors show that the Type I and Type II error rates can be controlled by judicious
selection of the parameters (K0,K1,K2). Specifically, they show that for a desired Type
I error rate of α, setting the ratio K0/K1 = (1 − α)/α will place an upper bound on the
Type I error of their test at α, while a grid search over the value of the ratio K2/K1 can
be performed to obtain the desired Type II error rate.
To select the optimal study design that minimizes the expected loss, the following two-step
procedure is followed:
1. If Lstop(Xj) ≤ Lcont(Xj), the experiment is stopped at interim look j. If at that point
Xj is in the rejection region, Rj , reject the null; otherwise accept.
2. If Lstop(Xj) > Lcont(Xj), then continue the experiment for one more look at the data
and repeat steps 1 and 2.
Because of the iterative nature of this study design, the stopping time of the trial, denoted
M , is not pre-fixed but rather is a random integer. The authors show in their Theorem
1 that for K2 > 0, M is a stopping time satisfying P (M < ∞ | θ) = 1. In other words,
if K2 > 0, then the experiment is guaranteed to terminate at some point and not go on
forever.
Extensions
In this section I discuss my adaptation of the Cheng and Shen methodology outlined above.
First, note the form of the rejection region, Rj , defined in (3). The test statistic checked at
every interim look is:
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P (θ > 0|Fj)
P (θ ≤ 0|Fj) , (4)
which is easily identified as the Bayes factor for a model with θ > 0 compared to one
with θ ≤ 0 under an assumption of equal prior odds for both hypotheses, a reasonable and
uninformative a priori assumption with respect to favoring one hypothesis over the other.
Note, also, the striking similarity between this test statistic and that of the classic Wald
SPRT [14] which can also be interpreted as a Bayes factor, although comparing two simple
hypotheses. It should not be surprising, then, that the critical values for those two test
statistics are so similar. For Wald’s SPRT, the null hypothesis is rejected once the Bayes
factor is greater than (1− β)/α, and is accepted if the Bayes factor is less than β/(1− α)
where α and β are the Type I and Type II errors, respectively. If at any given interim check
of the data either of those thresholds is crossed, the experiment is stopped; otherwise more
subjects are enrolled until a decision can be made.
Second, I examine the stopping rule derived by Cheng and Shen; specifically that the study
is stopped once Lstop(Xj) ≤ Lcont(Xj), or equivalently, when
2K2Bj+1 + E
(
min
[
E{L(θ,A)|Fj+1}, E{L(θ,R)|Fj+1}
]∣∣∣Fj)
≥ min[E{L(θ,A)|Fj}, E{L(θ,R)|Fj}]. (5)
In letting:
Yj = min
[
E{L(θ,A)|Fj}, E{L(θ,R)|Fj}
]
,
the authors show, by Jensen’s inequality, that:
E(Yj+1|Fj) ≤ min
(
E
[
E{L(θ,A)|Fj+1}
∣∣Fj], E[E{L(θ,R)|Fj+1}∣∣Fj]) = Yj . (6)
Following the notation in (6), the stopping rule (5) can be rewritten as
2K2Bj+1 ≥ Yj − E(Yj+1|Fj). (7)
By the proof of Theorem 1 in [18] (or (6) above), 0 ≤ Yj−E(Yj+1|Fj), with equality coming
by taking the limit as j → ∞ [18]. By taking K2 > 0 it can be ensured that the experi-
ment will reach a stopping time, M < ∞. However, I argue that, in the setting of digital
marketing, it is not unreasonable to set K2 = 0.
First, consider that the primary concern here is that of a mobile or digital marketer serv-
ing ads to his customers. If that marketer has the ability to send an ad to as many as
500,000 customers, the cost of sending a campaign out to 200,000 people versus 100,000,
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for example, is practically negligible; even if K2 is not truly zero, it should be very, very
close. Secondly, a marketer will likely be operating from the standpoint of wanting to run
a campaign for some number of pre-specified weeks, but with the option to stop if results
show themselves to be significant before that point. In practice, therefore, the experiment
would never run for an infinite amount of time. The sequential monitoring procedure simply
allows the marketer to monitor the campaign continuously and stop the experiment at any
time, with all of the results maintaining statistical validity with respect to the Type I error
rate whenever the campaign is halted.
Further, by recognizing that the test statistic (4) can be interpreted as a Bayes factor, I
propose that the test can easily be extended to two-sided hypotheses of the form:
H0 : θ = 0 vs. H1 : θ 6= 0,
by altering the test statistic to:
P (θ 6= 0|Fj)
P (θ = 0|Fj) , (8)
with a rejection region of
Rj =
{
Xj : P (θ 6= 0|Fj)
P (θ = 0|Fj) ≥ cα/2
}
, j = 1, 2, . . . (9)
where cα/2 is a threshold cutoff, the value of which is selected to ensure a desired Type I
error rate, α. Because I set K2 = 0, the rejection region above also doubles as the stopping
rule: If Xj ∈ Rj , stop the experiment and reject the null hypothesis; otherwise, continue
enrolling customers into the study. Such a stopping rule is very similar to that of the Wald
SPRT. Via simulation (results in later section), I show that the same cα/2 = (1−α/2)/(α/2)
stopping rule adopted by Cheng and Shen maintains the desired Type I error rate at α.
Additionally, because the hypothesis test is two-sided, the stopping rule encompasses both
superiority and inferiority of the treatment arm.
Estimation
Any number of estimation procedures would work under this framework. I prefer a Bayesian
approach to the problem, because a posteriori comparisons and transformations are greatly
simplified under a Bayesian framework, and because it is also appealing to assign a proba-
bility of being the best performing arm to each arm of a multivariate A/B test - something
that is not feasible in a frequentist framework. Specifically, I choose to estimate parame-
ters via a logistic regression, which provides the flexibility to additionally control for any
demographic variables available if desired, as well as to extend the model to easily include
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multiple treatment groups and any interactions between treatment group and demograph-
ics, all in one single estimation procedure. The simple two-arm model can take the following
form:
logit(pi) = α+ β ∗ trti +
k∑
j=1
γjzj , (10)
where pi is the probability of a success (e.g., a conversion), trti is a variable capturing
whether person i is in the treatment or control group, each zj is one of k optional de-
mographic variables to additionally control for, and Θ = (α, β, γ1, . . . , γk) is a vector of
parameters to be estimated by the model. The main parameter of interest is β, and the
hypothesis test can be written:
H0 : β = 0 vs. H1 : β 6= 0.
Note that β captures the log-odds of success for the treatment group compared to the con-
trol group, though it can easily be transformed to give the estimated probability of success
in each group. The Bayes factor (8) can be calculated by comparing the model that includes
the treatment variable to one that does not. As model complexity grows, and as the model
is extended to accommodate multivariate A/B tests, a fully Bayesian framework can prove
computationally intensive, particularly when evaluating tens or hundreds of campaigns at
once. In practice, therefore, the parameters of the model can be estimated using standard
statistical software, e.g., via the glm function in R, with samples from the posterior distribu-
tion of the parameters generated using the functionality of R’s arm package. Additionally,
the Bayes factor can be approximated by using Schwarz’s Bayesian Information Criterion
(BIC) from the fitted models [23, 24, 25], which also greatly reduces computation time.
Multivariate A/B Tests and Multiple Testing
The methodology outlined to this point covers only a simple two-arm A/B test. In this
section, I present extensions of the results above to multivariate (> 2 arm) A/B tests.
The main multiple comparisons problem is that the probability an experimenter incorrectly
concludes that there is at least one statistically significant result across a group of tests,
even when there are in fact no real associations, increases with each additional test [3, 4, 26].
A related issue is that, in a setting where actual non-zero effects do exist for some of the
tests, an experimenter applying multiple tests may find additional statistically significant
results that are not real [26].
Several approaches have been developed to address the multiple comparisons issue. The
most common of these is the Bonferroni correction, which divides the desired Type I error
rate, α, by the number of hypotheses being tested, m, yielding an adjusted Type I error
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rate of α∗ = α/m for each of the m tests. Other methods for controlling the Type I error
rate include the Sˇida´k correction and the Holm-Bonferroni correction, among others [see,
e.g., 27]. All of these procedures aim to control the familywise error rate (FWER) across
the group of tests at α. The main drawback to Bonferroni-type procedures is that the
Type I error problem is adjusted at the expense of the Type II error, meaning the power of
the statistical test can be greatly reduced using one of these adjustments. An alternative
approach to the multiple comparisons problem is to, instead of controlling the overall Type
I error rate, control the False Discovery Rate (FDR). In doing so, the researcher is able to
ensure that among all tests declared statistically significant, only a certain percentage are
expected to be false positives [28]. Under FDR adjustment, the test is less conservative with
respect to Type I error, though the researcher will have confidence that a high percentage
of the significant results detected represent real differences. A common thread between
methods controlling the FWER and those controlling the FDR is that both do so by means
of a p-value adjustment.
An alternative approach to the multiple comparisons problem is described by Gelman, et.
al. [26], wherein the authors shift the multiple comparisons problem into a modeling is-
sue and address it by operating from a Bayesian multilevel modeling framework. Unlike
FWER or FDR adjustments which, in essence, keep point estimates stationary and adjust
for multiple comparisons by making confidence intervals wider (or, equivalently, by ad-
justing the p-values), the multilevel modeling approach instead shifts point estimates and
their corresponding intervals closer together - a process known as “shrinkage” or “partial
pooling.” In this way, the estimates from a multilevel model naturally make comparisons
more conservative by increasing the likelihood that any intervals for comparisons contain
zero [26]. At the same time, the method does not correct for multiple comparisons at the
expense of the power of the test, unlike many of the traditional methods discussed above [26].
Rather than operating from the standard Type I error paradigm, Gelman, et. al. argue
that more troublesome issues are when either: 1. estimators have the incorrect sign, or 2.
estimators declare an effect to be small when it is actually large, or declare it is actually
large when in fact it is near zero. They dub these errors of sign, and errors of magnitude -
Type S and Type M errors, respectively. While the multilevel Bayesian approach addresses
Type S and Type M errors, it also does well to control for the conventional Type I error
while maintaining good power. Additionally, given the Bayesian nature of the analysis
proposed thus far, I find it desirable to address the multiple comparison issue in a very
natural Bayesian approach as opposed to making p-value adjustments since p-values are
inherently very non-Bayesian. Simulation results summarizing the performance of the full
multivariate A/B testing methodology are presented in a later section, but first consider
how the approach of Gelman, et. al. [26] can be applied to the method presented thus far.
Recall that in a simple two-arm A/B test, the comparison between the treatment and
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control group can be made by fitting the model given by (10). In an (m+ 1)-arm A/B test
(m > 1), a natural extension to (10) would be:
logit(pi) = α+
m∑
r=1
βr ∗ trti,r +
k∑
j=1
γjzj , (11)
where now trti,r is an indicator for whether person i was on arm Br, and βr is the corre-
sponding coefficient capturing the log-odds of success in group Br compared to the baseline
group, A. However to account for multiple comparisons under (11), some kind of p-value
adjustment would need to be made to adjust the FWER or FDR of the test. Instead, I
propose the following multilevel model based on [26]:
logit(pi) = αr[i] +
k∑
j=1
γjzj , (12)
where αr[i] captures the log-odds of success in person i’s arm of the experiment. And
αr ∼ N(µ, σ2α).
The caveat is that now r = 1, 2, . . . ,m,m + 1, meaning that the control group’s success
rate is also part of the pooling estimation. I believe this is reasonable in the sense that it
is not unrealistic to assume these are all realizations from a common distribution - it is the
same outcome being measured in each arm of the experiment, and it seems plausible that,
across multiple experiments, some arms might perform better than baseline, some worse,
and some very similarly. Assume α1 captures the log-odds in the control group, then the
multiple hypotheses being tested are of the form:
H0 : αr − α1 = 0 vs. H1 : αr − α1 6= 0, ∀r ≥ 2 (13)
As before, the model (12) can be fit in R, in this case by using the glmer function in
the lme4 package, with posterior simulations given by the arm package. It is also easy to
extend the model to obtain subgroup estimates by treatment group. For more details on
the multiple testing procedure, the reader is encouraged to see [26].
Simulation Results
In this section simulation results for the full method outlined above are presented, combin-
ing the estimation procedure of (12) with the decision rule given by (9). Table 2 summarizes
the average expected outcomes of five hypothetical multivariate A/B experiments, each of
which is a five-arm (four treatment + one control) experiment with equal allocation in each
arm. The results presented for each multivariate A/B experiment represent an average over
1,000 simulated trials. The hypotheses being tested are two-sided hypothesis tests taking
13
the form of (13). All hypothesis tests are carried out at the α = 0.05 level, yielding a cutoff
value of cα/2 = 39. For convenience a maximum of 20,000 people in each arm is enforced,
and the data is checked after every 500 enrollments in each arm, for a total of 40 interim
looks at the data. The fields in Table 2 are as follows:
Table 1: Results of Interest from Simulated Experiments
Field Description
p0
Probability of success in the control group, i.e. baseline
success rate.
pr Probability of success in treatment group r.
Power
Estimated power to detect a difference between each arm and
baseline; formally P(reject H0 | H1 True).
Type I Error (αˆ)
Estimated Type I Error for each arm;
formally P(reject H0 | H0 True)
N Average sample size required in each arm across all simulated trials
Fixed-Sample Avg. Power
Average power for a fixed-sample design given the observed N
from each simulated trial without multiple testing correction.
Fixed-Sample Avg. Power (Bonferroni)
Average power for a fixed-sample design given the observed N
from each simulated trial with a Bonferroni correction.
FWER
Familywise Error Rate. Percentage of simulated trials producing
at least one false positive.
FDR
False Discovery Rate. Percentage of statistically significant results
that are actually false positives.
Per-test αˆ Average Type I Error rate across all arms where H0 is true.
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From Table 2 it’s clear that the proposed method almost universally outperforms a standard
fixed-sample design under a Bonferonni correction with respect to power. Surprisingly, even
though the proposed method accounts for multiple testing, it also outperforms a standard
fixed-sample design with no multiple testing adjustment with respect to power and Type I
error in all but two of the 20 arms. The FDR rates are also quite good across all experi-
ments, although it is important to note that only the test with p0 = 0.50 had more than one
arm where the null hypothesis was true. Still, the results in Table 2 provide a good overview
of the performance of the methodology where there are only a handful of hypotheses being
simultaneously tested (only 4 comparisons being made) and where the null hypothesis is
not true in most arms.
Table 3 below displays analogous results to those in Table 2 above, but for 11-arm (ten
treatment + one control) experiments with equal allocation in each arm. In each experi-
ment, the null hypothesis of no treatment effect is true in five out of ten of the arms. To
conserve space, the results for only two (instead of five) such experiments are presented:
one with p0 = 0.5, and the other with p0 = 0.05. As before, the results presented for each
multivariate A/B experiment represent an average over 1,000 simulated trials; all hypothesis
tests were two-sided and carried out at an α = 0.05 level; and a maximum of 20,000 people
in each arm was enforced, with interim checks at every 500 enrollments for each arm. Even
in this scenario, the proposed method performs no worse than a Bonferroni-corrected exper-
iment with respect to power, and for “larger” differences between treatment and control the
proposed method far outperforms it - even doing better, again, than fixed-sample designs
with no multiple testing correction. Of particular note, the FWER is controlled below the
α = 0.05 level, and the FDR is quite low, between 1% and 1.5% for both experiments.
Another attractive aspect of this method is that in fitting the logistic model under a Bayesian
framework, it is easy to obtain, via posterior simulation, the probability corresponding
to each arm that it is the best performing arm in the study at each interim check, or
P (pr∗ = maxr(pr) | Fj). The result is a procedure that not only quantifies lift over baseline
and whether that lift is statistically significant or not, but also through these posterior prob-
abilities provides a means to compare the strength of evidence against the null hypothesis
for each of the arms in the study to one another. In other words, if two arms show significant
lift over baseline and one has a point estimate of 0.03 and the other 0.02, without digging
much deeper it would be reasonable to conclude that they performed very similarly to each
other. If however, you have readily available the fact that P (p0.03 = maxr(pr) | Fj) = 0.70,
while P (p0.02 = maxr(pr) | Fj) = 0.25, the arm with the point estimate of 0.03 now car-
ries more weight than if one only knew the point estimates. Figure 1 below shows how
these probabilities change throughout a trial as the data collected grows. Specifically, Fig-
ure 1 plots the average of P (pr∗ = maxr(pr) | Fj) for each j and for each treatment arm
corresponding to the simulated trial in Table 3 with p0 = 0.5.
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Figure 1: Plot of P (pr∗ = maxr(pr)) vs. N; 11-arms, p0 = 0.5
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For convenience, all five arms with a success rate of 0.5 are condensed into one line in Figure
1. As expected, the arm with a success rate of 0.53, the maximum among all arms in the
experiment, breaks away from the rest and converges towards one, while the probabilities
of all the other arms being the best slowly fade towards zero. This phenomenon is not
unique to this particular simulation, as all simulations presented in Table 2 and Table 3
exhibited nearly identical trends. Indeed, this makes intuitive sense. At the beginning of
the experiment we don’t know anything about any of the arms in the experiment, so a priori
all arms have an equal probability of being the best. On average, however, as more data is
accumulated, we’re able to more accurately identify which arm is the best performing arm
in the study.
Additional Comparisons
It is worth noting that the sequential monitoring portion of the method presented in this
paper is also quite similar to that of Johari, Pekelis, and Walsh [21] (henceforth referred
18
to as JPW), who appear to have independently derived very similar results to those in
[18]. Indeed, they are largely concerned with the same problem presented in this paper -
specifically sequential monitoring and multiple comparisons adjustment in A/B tests as it
relates to digital marketing. The method in [21], however, does not carry out model fitting
and estimation in a fully Bayesian framework, and employs an FDR correction for multiple
comparisons, both of which differ from the method presented here.
Briefly, JPW [21] (or, in a more accessible version, Pekelis, et al [29]) also define their test
statistic as the Bayes Factor given by (8), which they denote Λn. They then invert Λn to
obtain a p-value, p∗. For a given Type I error, α, p∗ would be interpreted in the usual way.
For a family of p-values, p∗i , i = 1, . . . ,m obtained from a multiple-testing situation, the
authors apply an FDR correction, e.g. [28], to control the false discovery rate. To compare
the method presented here to that of JPW, I applied the method outlined in [21, 29] to the
same 11-arm simulated data that I applied the proposed method to, the results of which
were presented in Table 3. Table 4 below shows the results when the approach of [21, 29] is
applied to that same data. Specifically, to implement their approach I fit a standard logistic
regression model with an indicator for each arm in the experiment as in (11) and calculated
the Bayes Factor corresponding to each covariate, βr, via a BIC approximation. I then
took the inverse of each Bayes Factor to obtain the corresponding p-values, and applied
the standard Benjamini-Hochberg correction [28] to the p-values at each interim check to
control the FDR at 0.05.
It is immediately obvious from Table 4 that the method of JPW, as I have applied it, is
extremely conservative when applied to this simulated data. While it’s true that the FDR is
nearly zero, as is the FWER, in both simulated experiments, this is achieved at the expense
of the test’s power. This is especially the case when the true difference between arms is
small. As the difference between arms increases, the JPW approach begins to perform
better, although the average sample size required to detect that difference is still much
larger than what is seen from the method I have proposed. Table 5 provides a side-by-side
comparison of the proposed method and the JPW method for a handful of metrics, clearly
showing that the proposed method has much higher overall accuracy (a lower overall error
rate) and accrues substantially fewer subjects, on average, than does JPW’s method. On
the other hand, JPW present a method that achieves a lower FDR and a lower false positive
rate.
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Table 5: Proposed Method and JPW Method: Simulation Comparison
p0 = 0.50 p0 = 0.05
Proposed Method JPW Method Proposed Method JPW Method
FWER 0.038 0.001 0.039 0.001
FDR 0.014 0.001 0.010 >0.001
Overall Error Rate
((FP + FN)/Ntests)
20.00% 33.98% 7.61% 18.19%
Avg. sample accrued for
tests where pr 6= p0 13,684.1 17,657.2 9,372.1 14,101.9
It is possible that some of the difference observed between the two methods is attributable
to how I have implemented the JPW method. In particular, in [21, 29] the authors dis-
cuss how an important part of their method involves selecting an “optimal prior” for the
parameter of interest, something that they base on over 40,000 historical A/B tests run on
their company’s platform [21]. Still, as that appears to be proprietary information, it is not
clear how an independent researcher can adequately evaluate their method without use of
anything more than a non-informative prior. Because both methods presented here assume
the same prior distribution that is imposed by using the BIC to approximate the Bayes Fac-
tor, specifically a unit information prior [25], I think the comparison is fair. Additionally,
anyone wishing to implement an approach like this for the first time or on an ad hoc basis
wouldn’t have much, if any, historical data to use to tune their prior, so it is important to
evaluate each method’s performance in the setting with little prior information. Yet, it is
also important to consider that the JPW method would likely see improved performance
given a well tuned prior for the regression coefficients in the logistic regression.
Another natural comparison that is not presented here would be this method’s performance
relative to an experiment with an O’Brien Fleming (OBF) stopping rule [8]. Cheng and Shen
[18] present this comparison in Table 1 of their paper for a simple two-arm test. When the
minimum detectable difference is correctly specified, an OBF design will perform just as well
as this method with respect to Type I error, power, and average sample size. If, however,
the minimum detectable difference is overestimated, the power in an OBF design will take
a substantial hit. Alternatively, if the minimum detectable difference is underestimated,
the study will be overpowered and result in a longer study that enrolls more people than
needed, on average, than the sequential Bayesian design.
Discussion
Additional Considerations
I believe the most natural extension in this framework would be allowing for outcome-
adaptive randomization throughout the experiment. That is, as the experiment is ongoing,
21
the study would learn from itself and use the data that has already been accrued to propor-
tionately allocate more people to the best performing arms, while reducing the allocation
percentage in arms that are not performing well. Formally, let
pj,r∗(max) = P (pr∗ = max
r
(pr) | Fj)
be the probability that arm r∗ is the best performing arm at interim check j. Then, moving
forward, the percentage of study participants to be allocated to any arm r = r∗ after interim
check j can be given by [10, 11]:
Allocj+(r
∗) =
{pj,r∗(max)}h∑
r {pj,r(max)}h
, (14)
where 0 ≤ h ≤ 1 is a parameter that adjusts how aggressive the adaptive procedure will
be. Setting h = 0 yields conventional randomization, while h = 1 gives Allocj+(r
∗) =
pj,r∗(max). Thall and Wathen [11] note that h = 1/2 typically works well, while many
desirable properties are also obtained setting h = n/2N , where n/N is the current sample
size divided by the maximum sample size for the experiment, though it could also be thought
of as the fraction of the study completed to that point if no maximum sample size has been
set. The adaptive randomization could be constructed so that (14) does not include the
control group, and instead is only calculated for each of the different treatment arms in the
study. Such an approach would likely help to hone in on the best performing variant more
quickly, but might not be desirable in a setting where the goal is to accurately measure
the treatment effect in each arm, because discontinuing allocation to some arms early on in
the study should result in more variable estimates in those arms, meaning they’ll be pulled
closer towards the overall mean across all arms via (12). Therefore, depending on the goal
of the study, this is potentially a decision the researcher must make before conducting the
experiment. More work is required to determine exactly how well an adaptive randomization
scheme like (14) would perform when used together with this method.
Conclusions
In this paper I have presented a method for implementing multivariate A/B testing that I
believe can be quite useful in online and mobile marketing. The method primarily draws
on previous work in clinical trials methodology [18] and applied social sciences research
[26] to create a unified approach to both continuous monitoring of A/B tests, and how to
adequately account for multiple comparisons in the event of a multivariate A/B test. When
compared to other existing methods, the method proposed herein performs quite favorably.
Recall the questions presented on pages one and two of this paper. By approaching the
problem from a Bayesian perspective, a researcher can easily rank and compare arms, or
variants, to each other by making use of the posterior simulations and calculating pj,r∗(max)
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for each arm at each interim check, in addition to determining whether each is significantly
better than baseline using the sequential monitoring procedure. Additionally, by not spec-
ifying the sample size, N , in advance, a researcher does not need to worry about setting a
minimum detectable difference in the planning stage and thereby potentially enrolling too
few or too many people in his study. The method also gives the researcher the freedom
to look at the data as often as he pleases, with valid results no matter when he decides
to stop the study. Additionally, while the method presented here was done so with binary
outcomes in mind, the same rules would apply for a continuous outcome variable.
From the standpoint of an applied researcher, a major advantage of this approach is the
relative ease with which it can be carried out. The models to be fitted are familiar, and
approximating the Bayes factor using the BIC is straightforward and computationally in-
expensive. Using the BIC approximation to the Bayes factor amounts to assuming a unit
information prior for all of the parameters in the model, a conservative assumption with
respect to rejecting the null hypothesis [25]. Coupled with a conservative rejection criterion
of cα/2 = (1− α/2)/(α/2), the proposed method can overall be thought of as conservative
with respect to Type I error, FWER, and FDR; and that is exactly what is seen in the
results presented in Table 2 and Table 3. A valid question about this method is how well
it would perform for an experiment with greater than 11 arms - as that is not a scenario
considered here. In practice, however, an A/B test comparing more than 10 different vari-
ants to a control group is quite rare. Overall, I believe the method would be most useful
when a researcher wants to run an experiment with somewhere between two and 20 arms
for some pre-specified amount of time, but with no cap on the number of people that can
be enrolled in the study over that time period. This falls neatly in line with the idea of
running an experimental campaign for some pre-determined number of weeks, with the hope
of continuously monitoring the campaign and terminating the experiment once one or two
or any arbitrary number of variants show statistically significant lift over baseline. While
digital marketing and advertising provide a natural fit for this methodology, it should also
work well for an experiment in any field with similar criteria.
References
[1] Curtis L. Meinert. Clinical Trials Handbook: Design and Conduct. John Wiley & Sons,
Inc., Hoboken, NJ, USA, 2012.
[2] The Office of Biostatistics and the Office of New Drugs in the Center for Drug Eval-
uation and Research. Guidance for Industry: Adaptive design clinical trials for drugs
and biologics. Report, U.S. Food and Drug Administration, 2010.
23
[3] P. Armitage, C. K. McPherson, and B. C. Rowe. Repeated significance tests on accu-
mulating data. Journal of the Royal Statistical Society, Series A, 132:235–244, 1969.
[4] Cyrus R. Mehta. Lecture 1: Introduction to flexible clinical trials. In Sequential Design
and Interim Monitoring. Harvard University & Cytel Software Corporation, 2004.
[5] David L. DeMets and K. K. Gordon Lan. Interim analysis: The alpha spending function
approach. Statistics in Medicine, 13:1341–1352, 1994.
[6] Stuart J. Pocock. Group sequential methods in the design and analysis of clinical trials.
Biometrika, 64:191–199, 1977.
[7] R. Peto, M. C. Pike, P. Armitage, N. E. Breslow, D. R. Cox, S. V. Howard, N. Mantel,
K. McPherson, J. Peto, and P. G. Smith. Design and analysis of randomized clinical
trials requiring prolonged observations of each patient, I. Mortality results. British
Journal of Cancer, 34:585–612, 1976.
[8] Peter C. O’Brien and Thomas R. Fleming. A multiple testing procedure for clinical
trials. Biometrics, 35:549–556, 1979.
[9] S. B. Tan and D. Machin. Bayesian two-stage designs for phase II clinical trials.
Statistics in Medicine, 21:1991–2012, 2002.
[10] Peter F. Thall and J. Kyle Wathen. Covariate-adjusted adaptive randomization in a
sarcoma trial with multi-stage treatments. Statistics in Medicine, 24:1947–1964, 2005.
[11] Peter F. Thall and J. Kyle Wathen. Practical bayesian adaptive randomization in
clinical trials. European Journal of Cancer, 43:859–866, 2007.
[12] J. Kyle Wathen and Peter F. Thall. Bayesian adaptive model selection for optimizing
group sequential clinical trials. Statistics in Medicine, 27:5586–5604, 2008.
[13] Valen E. Johnson and John D. Cook. Bayesian design of single-arm phase II clinical
trials with continuous monitoring. Working paper series, paper 47, University of Texas,
MD Anderson Cancer Center, 2008.
[14] Abraham Wald. Sequential tests of statistical hypotheses. Annals of Mathematical
Statistics, 16:117–186, 1945.
[15] M. Kulldorff, R. L. Davis, M. Kolczak, E. Lewis, T. Lieu, and R. Platt. A maximized
sequential probability ratio test for drug and vaccine safety surveillance. Sequential
Analysis, 30:58–78, 2011.
[16] D. G. Hoel, G. H. Weiss, and R. Simon. Sequential tests for composite hypotheses
with two binomial populations. Journal of the Royal Statistical Society, Series B,
38:302–308, 1976.
24
[17] William Q. Meeker Jr. A conditional sequential test for the equality of two binomial
proportions. Journal of the Royal Statistical Society, Series C, 30:109–115, 1981.
[18] Yi Cheng and Yu Shen. Bayesian adaptive designs for clinical trials. Biometrika,
92:633–646, 2005.
[19] Peter Armitage. Numerical studies in the sequential estimation of a binomial parame-
ter. Biometrika, 45:1–15, 1958.
[20] Peter Armitage. Sequential Medical Trials. Thomas, Springfield, IL, USA, 1960.
[21] Ramesh Johari, Leo Pekelis, and David J. Walsh. Always valid inference: Bringing
sequential analysis to A/B testing. arXiv preprint, arXiv:1512.04922, 2015.
[22] Alexandru D. Corlan. Medline trend: automated yearly statistics of pubmed results
for any query. http://dan.corlan.net/medline-trend.html, 2016. Accessed: 2016-
01-13.
[23] Gideon Schwarz. Estimating the dimension of a model. Annals of Statisitics, 6:461–464,
1978.
[24] Robert E. Kass. Bayes factors in practice. The Statistician, 42:551–560, 1993. Special
issue: Conference on practical Bayesian statistics.
[25] Adrian E. Raftery. Bayes factors and BIC: Comment on “A critique of the Bayesian
information criterion for model selection”. Sociological Methods & Research, 27:411–
427, 1999.
[26] Andrew Gelman, Jennifer Hill, and Masanao Yajima. Why we (usually) don’t have to
worry about multiple comparisons. Journal of Research on Educational Effectiveness,
5:189–211, 2012.
[27] Jason C. Hsu. Multiple Comparisons: Theory and Methods. Chapman and Hall, Lon-
don, UK, 1996.
[28] Yoav Benjamini and Yosef Hochberg. Controlling the false discovery rate: A practical
and powerful approach to multiple testing. Journal of the Royal Statistical Society,
Series B, 57:289–300, 1995.
[29] Leo Pekelis, David Walsh, and Ramesh Johari. The new stats engine. Technical report,
Optimizely, Inc., 2015. Accessed: 2016-08-22.
25
